Drug intelligence / Profile preview

KP183

Development stage: Preclinical
Lead developer: Korea Pharma
Modality: Small Molecules
Administration: Oral

Overview

KP183 is a drug candidate currently in preclinical development by the South Korean pharmaceutical company **Korea Pharma**. The agent is being investigated for the treatment of **depression**. As of the current pipeline status, KP183 is undergoing early-stage research to evaluate its safety and efficacy profile for mood disorders. Specific pharmacological details, including its molecular target, chemical structure, and precise mechanism of action, have not been publicly disclosed by the sponsor.

Beyond the preview

Go deeper on KP183.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KP183.

Explore the full profile